<DOC>
	<DOCNO>NCT00001959</DOCNO>
	<brief_summary>This study examine effectiveness drug pirfenidone treat focal segmental glomerulosclerosis ( FSGS ) . Patients disease kidney fibrosis ( scar ) proteinuria ( excessive excretion protein urine ) . About half patient FSGS eventually require kidney dialysis transplant . Steroids , currently use treat disease , effective minority patient . Other drug , cyclosporin cyclophosphamide , improve proteinuria small percentage patient serious side effect . Patients FSGS wish participate study undergo pre-study evaluation blood urine test . Patients must stable dose ACE inhibitor ( drug lower blood pressure reduce proteinuria ) list 6 month start pirfenidone therapy . ( Patients already take ACE inhibitor start drug ; tolerate ACE inhibitor give different drug . ) Patients elevate cholesterol take cholesterol-lowering drug . A diet contain approximately 1 gram protein per kilogram body weight per day recommend . Patients take pirfenidone mouth 3 time day 12 month . Blood urine test month , either NIH patient 's local kidney specialist . They collect two 24-hour urine sample begin treatment period , 2-month interval throughout study , 6-month follow-up . Patients also ask give three five tube blood urine sample analysis study . In animal study , pirfenidone improve kidney function proteinuria reduce kidney scar rat disease similar FSGS . In human study , pirfenidone improve breathing survival patient lung fibrosis .</brief_summary>
	<brief_title>Pirfenidone Treat Kidney Disease ( Focal Segmental Glomerulosclerosis )</brief_title>
	<detailed_description>The objective pilot phase II trial evaluate ability pirfenidone , novel anti-fibrotic agent , reduce proteinuria slow rate progression renal insufficiency patient focal segmental glomerulosclerosis ( FSGS ) . We enroll 25 patient renal biopsy proven FSGS evidence impair renal function ( glomerular filtration rate , GFR , 10-80 ml/min ; 1/02 must GFR great 25 ml/min ) assess 4 variable Modification Diet Renal Disease equation . As standard care therapy , patient also receive angiotensin convert enzyme inhibitor ( ACEI ) therapy , receive HMG Co-A reductase inhibitor drug hypercholesterolemic . Preliminary evaluation assure patient meet study requirement , evaluation period use ensure patient maximal conservative therapy prior baseline period . Patients receive treatment pirfenidone daily , dose adjust body weight level kidney function . The primary end point decrease glomerular filtration marker glomerular injury ; reduction proteinuria secondary end-point . If pilot study suggest drug delay progression renal insufficiency reduces proteinuria patient FSGS , proceed large scale randomize , placebo-controlled study .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Adults great equal 18 year age . 2 . Patients provide informed consent . 3 . Biopsy proven FSGS . 4 . Glomerular filtration rate least 25 80 ml/minute assess 4 variable Modification diet renal disease GFR equation . 5 . At least 6 month renal function data must available prior patient 's receive pirfenidone , renal function must show rate decline great equal 0.4 ml/min/month baseline period . 6 . Patients must receive glucocorticoid , cyclophosphamide , mycophenolate immunosuppressive drug least 2 month prior study period . 7 . Patients must receive cyclosporin least 6 month prior study period . 8 . Patients must take angiotensin convert enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) stable dose least 6 month , unless intolerant class medication . 9 . Patients HIV seropositive receive standard care HIV disease ( patient receive immunemodulating therapy exclude ) . 10 . Women childbearing potential must maintain effective birth control regimen ( oral contraceptive , intrauterine device , barrier plus spermicide ) . 11 . Men advise although Ames test negative evidence mutagenicity , consider use contraceptive study period well . EXCLUSION CRITERIA : 1 . Inability give inform consent cooperate study . 2 . Known intolerance pirfenidone . 3 . Evidence FSGS associate additional primary secondary glomerular disease ( e.g . diabetes , membranous nephropathy , IgA nephropathy ) . 4 . Recent ( within 6 month ) history myocardial infarction . 5 . History peptic ulcer within 6 month . 6 . History cerebrovascular disease manifest transient ischemic attack cerebrovascular accident within 6 month . 7 . Pregnancy , breast feeding inadequate birth control . 8 . History photosensitivity dermatitis . 9 . Concurrent drug treatment gemfibrozil , cyclosporin erythromycin , potassiumsparing diuretic drug may potentiate hyperkalemia , concurrent immunosuppresive medication . 10 . Requirement NSAID therapy . 11 . Requirement interleukin2 therapy immunemodulating medication . 12 . Existence condition would complicate implementation interpretation study . 13 . Renal transplant . 14 . Evidence significant hepatic disease , indicate serum transaminase great 3 time upper limit normal , protime great 2 second prolong .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Fibrosis</keyword>
	<keyword>Nephrotic Syndrome</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Renal Failure</keyword>
	<keyword>TGF-Beta</keyword>
	<keyword>Focal Segmental Glomerulosclerosis</keyword>
	<keyword>FSGS</keyword>
</DOC>